Whitnell & Co. grew its stake in Pfizer Inc. (NYSE:PFE) by 390.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,507 shares of the biopharmaceutical company’s stock after buying an additional 40,200 shares during the quarter. Whitnell & Co.’s holdings in Pfizer were worth $1,815,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. 1 North Wealth Services LLC purchased a new stake in shares of Pfizer during the third quarter worth about $29,000. Bourgeon Capital Management LLC purchased a new stake in shares of Pfizer during the third quarter worth about $32,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter worth about $34,000. IMA Wealth Inc. grew its holdings in Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 477 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new position in Pfizer during the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 71.52% of the company’s stock.
In related news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Scott Gottlieb purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.
NYSE PFE traded up $0.14 during trading on Friday, hitting $37.05. 24,924,227 shares of the stock traded hands, compared to its average volume of 23,366,957. The company has a market capitalization of $207.30 billion, a P/E ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67. The firm has a 50-day simple moving average of $36.62 and a 200-day simple moving average of $39.26. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The company’s revenue for the quarter was down 4.6% on a year-over-year basis. During the same period last year, the company earned $0.78 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.
Several equities analysts have weighed in on the company. Morgan Stanley cut their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Nine research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $44.02.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.